Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 146
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07512375 MY-EDUC — The Effectiveness of an ETP Programme in Myasthenia Gravis: a… |
MY-EDUC — The Effectiveness of an… | Myasthénie | À vérifier | NOT_YET_RECRUITING | En attente / non publié | University Hospital, Grenoble | Non communiqué | 2026-04 → 2027-06 | Ouvrir |
| NCT07499323 Talquetamab in Patients With Refractory Generalized Myasthenia Gravis |
Talquetamab | Myasthénie | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Noffar Bar | Non communiqué | 2026-03-20 → 2027-04-01 | Ouvrir |
| NCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) |
Telitacicept | Myasthénie | Phase 3 | RECRUITING | En attente / non publié | Vor Biopharma | China · Beijing Hospital, Beijing, China | 2026-01-13 → 2027-02-28 | Ouvrir |
| NCT06754020 TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis … |
Heart Rate Variability,HRV - ANSW… | Myasthénie | Non applicable | RECRUITING | En attente / non publié | Yi Ting Yeh | Taiwan · Yi Ting Yeh, New Taipei City, Taiwan | 2023-01-17 → 2027-12-31 | Ouvrir |
| NCT06312644 Study of Ultomiris® (Ravulizumab) Safety in Pregnancy |
Ultomiris | Myasthénie | À vérifier | RECRUITING | En attente / non publié | Alexion Pharmaceuticals, Inc. | United States, Australia, France, Germany, Italy, Sou… | 2024-12-16 → 2034-07-11 | Ouvrir |
| NCT07532707 Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria. |
IVIG (Intravenous Immunoglobulin) | Myasthénie | Non applicable | COMPLETED | En attente / non publié | Damascus University | Syria · Damascus University, Damascus, Syria | 2022-09-01 → 2023-10-30 | Ouvrir |
| NCT05644561 Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravuli… |
Ravulizumab | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Alexion Pharmaceuticals, Inc. | United States, Italy, Japan, Serbia, Switzerland · Re… | 2023-06-24 → 2028-06-30 | Ouvrir |
| NCT05332210 Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patien… |
HBM9161 Injection (680mg) | Myasthénie | Phase 3 | COMPLETED | En attente / non publié | Harbour BioMed (Guangzhou) Co. Lt… | China · Huashan Hospital, Fudan University, Shanghai,… | 2022-06-30 → 2024-04-26 | Ouvrir |
| NCT06220201 A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels… |
CC-97540 | Myasthénie | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | Juno Therapeutics, Inc., a Bristo… | United States, Belgium, France, Germany, Spain, Unite… | 2024-03-28 → 2027-07-15 | Ouvrir |
| NCT05374590 ADAPT Jr + — Evaluating Long-term Safety of Efgartigimod Administered I… |
Efgartigimod IV or Efgartigimod P… | Myasthénie | Phase 2/3 | ENROLLING_BY_INVITATION | En attente / non publié | argenx | United States, Belgium, Canada, France, Germany, Isra… | 2022-08-18 → 2029-09 | Ouvrir |
| NCT06106672 Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP… |
CNP-106 | Myasthénie | Phase 1/2 | ACTIVE_NOT_RECRUITING | En attente / non publié | COUR Pharmaceutical Development C… | United States · Atlantis Research, Miami, United Stat… | 2024-05-30 → 2026-08 | Ouvrir |
| NCT06193889 KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, … |
Standard lymphodepletion regimen | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | Kyverna Therapeutics | United States, Australia, Brazil, Germany, Saudi Arab… | 2024-08-28 → 2028-09 | Ouvrir |
| NCT06940323 Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA) |
Pregnancy Registry, Infants, Seru… | Myasthénie | À vérifier | RECRUITING | En attente / non publié | University of California, San Fra… | United States · University of California-San Francisc… | 2017-03-21 → 2035-06 | Ouvrir |
| NCT05265273 A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Ge… |
Nipocalimab | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | Janssen Research & Development, L… | United States, Japan, Netherlands, Poland · C.S. Mott… | 2022-07-20 → 2029-07-02 | Ouvrir |
| NCT07596901 Study of Aritinercept in Patients With Generalized Myasthenia Gravis |
Aritinercept | Myasthénie | Phase 1/2 | RECRUITING | En attente / non publié | Aurinia Pharmaceuticals Inc. | United States · Aurinia Investigational Site, Altamon… | 2026-04-22 → 2029-03-02 | Ouvrir |
| NCT06447597 A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gra… |
B007 | Myasthénie | Phase 2/3 | RECRUITING | En attente / non publié | Shanghai Jiaolian Drug Research a… | China · Affiliated Hospital of Zunyi Medical College,… | 2024-07-01 → 2026-12-30 | Ouvrir |
| NCT06359041 RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Pa… |
CABA-201 | Myasthénie | Phase 1/2 | RECRUITING | En attente / non publié | Cabaletta Bio | United States · Baylor College of Medicine Neurology … | 2024-12-17 → 2029-09 | Ouvrir |
| NCT04146051 Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Descartes-08 | Myasthénie | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Cartesian Therapeutics | United States, Canada · Allegheny Health Network, Pit… | 2019-12-04 → 2026-09-30 | Ouvrir |
| NCT07571525 TAILOR-MG — Thymic Disease, Autoimmunity, and Neuromuscular Junction In… |
TAILOR-MG — Thymic Disease, Autoi… | Myasthénie | À vérifier | NOT_YET_RECRUITING | En attente / non publié | IRCCS San Raffaele | Italy · IRCCS Ospedale San Raffaele, Milan, Italy | 2026-09-15 → 2029-12-01 | Ouvrir |
| NCT07337785 CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Dis… |
CD19/BCMA-targeted CAR-T cells | Myasthénie | Phase 1 | RECRUITING | En attente / non publié | Tongji Hospital | China · Tongji Hospital, Tongji Medical College, Huaz… | 2025-12-12 → 2028-11-01 | Ouvrir |
| NCT04524273 MINT — Myasthenia Gravis Inebilizumab Trial |
Inebilizumab | Myasthénie | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Amgen | United States, Argentina, Belarus, Brazil, Canada, Ch… | 2020-10-15 → 2029-06-07 | Ouvrir |
| NCT07593911 ArchAid-002 — A Study to Evaluate MTM-H-001 Injection in Adult Patients… |
MTM-H-001 Injection | Myasthénie | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Beijing GoBroad Hospital | China · Beijing GoBroad Hospital, Beijing, China | 2026-06 → 2031-06 | Ouvrir |
| NCT00704626 SAA — Serum Auto-Antibodies in Neurological Diseases |
SAA — Serum Auto-Antibodies in Ne… | Myasthénie | À vérifier | ENROLLING_BY_INVITATION | En attente / non publié | University of California, Davis | United States · University of California, Davis, Sacr… | 2002-01 → 2031-03 | Ouvrir |
| NCT07595653 POEMA — A Study to Evaluate the Impact of Efgartigimod on Overall Disea… |
POEMA — A Study to Evaluate the I… | Myasthénie | À vérifier | RECRUITING | En attente / non publié | argenx | Italy · A.O.U. Careggi, Florence, Italy | A.O.U. Cons… | 2026-02-25 → 2028-07 | Ouvrir |
| NCT04980495 ADAPT NXT — An Open-label Study to Investigate the Clinical Efficacy of… |
Efgartigimod IV | Myasthénie | Phase 3 | COMPLETED | En attente / non publié | argenx | United States, Austria, Belgium, Canada, France, Geor… | 2021-12-16 → 2025-10-06 | Ouvrir |